AIxCrypto Holdings, Inc. reported significant financial challenges in its latest 10-Q filing for the quarter ending June 30, 2026. The company recorded a net loss of $10.3 million for the six months ended June 30, 2026, compared to a loss of $4.3 million for the same period in 2025. This resulted in a loss per share of $0.73, a decrease from $2.76 in the prior year. Total expenses for the first half of 2026 reached approximately $7.3 million, up from $4.4 million in the previous year, driven primarily by increased general and administrative costs, which rose to $6.4 million from $3.9 million.

The company experienced a notable decline in its total assets, which fell to $7.4 million as of June 30, 2026, down from $31.3 million at the end of 2025. This decrease was largely attributed to a reduction in cash and cash equivalents, which dropped to $577,328 from $19.3 million, and a decline in digital assets, which decreased to $5.2 million from $10.3 million. Current liabilities also decreased to $1.7 million from $3.3 million, indicating some progress in managing obligations.

Strategically, AIxCrypto has undergone significant changes, including the discontinuation of its legacy biotechnology business as of May 21, 2026. The company is now focusing on its Real-World Asset (RWA) tokenization and Embodied Artificial Intelligence (EAI) initiatives. In January 2026, it established three new subsidiaries to support these efforts. The RoboShare platform, launched in June 2026, is positioned as a key operational priority, aimed at providing on-demand robotic services. However, the company has yet to generate revenue from this platform, with its first rental delivery targeted for August 2026.

Operationally, AIxCrypto's headcount has increased, contributing to higher administrative costs. The company reported a significant increase in sales and marketing expenses, which reached approximately $724,000 for the first half of 2026, reflecting its efforts to build brand awareness for its new initiatives. Despite these efforts, the company faces ongoing liquidity challenges, with an accumulated deficit of $150.3 million as of June 30, 2026. Management has indicated that it will continue to pursue cost normalization measures and explore monetization of digital asset holdings to address liquidity constraints.

Looking ahead, AIxCrypto's management has expressed concerns about its ability to continue as a going concern, given its limited cash reserves and the absence of committed financing. The company plans to focus on its digital asset treasury strategy and the commercialization of its physical AI activities through RoboShare, but acknowledges that there are no guarantees of revenue generation from these initiatives. The outlook remains uncertain as the company navigates these challenges while attempting to stabilize its financial position.

About AIxCrypto Holdings, Inc.

Qualigen Therapeutics is an early-stage biotech company developing cancer treatments, focusing on small molecule therapeutics targeting genetic structures like G-quadruplexes and RAS oncogenes. Its pipeline includes QN-302 for pancreatic cancer and Pan-RAS inhibitors for multiple cancers. The company collaborates with academic institutions, advances clinical trials, and seeks regulatory approval, aiming to address unmet medical needs in oncology markets.

This description was generated via AI from an annual report. Updated about 1 year ago.

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.

View the complete official filing on the SEC website.

Read on SEC.gov